(+/-)-Erdin | 3405-51-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: (+/-)-Erdin
• 英文别名: Erdin；5,7-dichloro-4-hydroxy-5'-methoxy-6-methyl-3,3'-dioxospiro[1-benzofuran-2,6'-cyclohexa-1,4-diene]-1'-carboxylic acid
• CAS: 3405-51-4；26891-81-6
• 化学式: C₁₆H₁₀Cl₂O₇
• 分子量: 385.157
• InChiKey: BAJDPELVDLJCSG-UHFFFAOYSA-N

物化性质

• 熔点：
  210-212°
• 沸点：
  701.3±60.0 °C(Predicted)
• 密度：
  1.73±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (+/-)-Erdin 生成 4,6-二氯-5-甲基-1,3-苯二酚
  参考文献：
  名称：

  Treatment of pulmonary hypertension during surgery with nitric oxide and vasodilators

  摘要：

  Purpose: To describe the effects of the combination of several therapies on the pulmonary circulation and cardiac function in a patient with severe pulmonary hypertension.Clinical features: We report the case of a female patient with chronic secondary pulmonary hypertension and cardiac failure who underwent right hemicolectomy under general anesthesia. Insertion of a pulmonary artery catheter before the operation revealed pulmonary artery pressure (PAP) of 55/24 mmHg which was lowered moderately by 40 parts per million (ppm) inhNO, During surgery, the patient presented an episode of atrial fibrillation with a slow, irregular heart rate of 45-50 min(-1) and variable systemic pressure. A dipyridamole DPD (0.2 mg.kg(-1)) bolus stabilized systemic pressure and increased heart rate and cardiac output. However, PAP did not change. Nitroglycerine infusion was started at 10 mg.hr(-1) shortly after the initiation of DPD, The patient responded favourably to combined inhNO, intravenous DPD and NTG therapy with a marked and sustained reduction of PAP and a systemic hemodynamic stability.Conclusion: We conclude that: 1) in combination with inhNO, DPD does not augment the inhNO-induced decrease in PAP; 2) DPD improves the hemodynamic profile and elevates cardiac output; 3) therapeutic combination (inhaled NO, NTG, DPD) has a potent effect an pulmonary pressure in cardiac failure patients.

  DOI：

  10.1007/bf03018946

文献信息

• Bausatz aus ineinandersteckbaren Winkelelementen
  申请人：Bökeler, Hans-Jörg

  公开号：EP0357950A2

  公开（公告）日：1990-03-14

  Die Erfindung betrifft einen Bausatz aus ineinandersteck­baren Winkelementen zur Erstellung von bepflanzbaren Sicht-, Schall- und Detonationsschutzmauern, Pflanztrögen, Hangab­stützungen, Stützen sowie Grundstücks- Weg- und Beetein­fassungen. Formsteine und -elemente von überwiegend gleich­schenkligem, winkelförmigem Querschnitt mit beliebigem, hauptsächlich 90- und 60-Grad- Innenwinkel und gleich­schenkligen Schenkelspitzen werden nach dem Maurerprinzip mit versetzten Stoßfugen verbaut zu frei stehenden oder ange­böschten Pflanzwänden und Stützen. Mit einem einzigen Win­kelelement können verschiedenartige, statisch belastbare Wände und Stützen trocken erstellt und die Hohlkammern be­wehrt und mit Mörtel vergossen werden. Für die Verdübelung der Horizontalfugen stehen mehrere Alternativen z.B. Rand­profilierungen und Steckdübel zur Verfügung. Weiterhin lassen sich die Bauelelemente im jeweils entspre­chenden Maßstab in verschiedenen Materialien als Hochbausys­stem in Beton, als Möbelstücke und Raumteiler in Holz oder als Modellbauwerke in Kunststoff verwenden(Fig.16).

  本发明涉及一种联锁角构件套件，用于建造可种植植物的隐私墙、防噪音和防爆墙、植物槽、斜坡支撑、支柱以及物业道路和花坛边缘。模制砖和构件的横截面主要为等腰、角形，具有任意（主要是 90 度和 60 度）内角和等腰脚尖，根据砌砖原理，用交错的对接接头进行安装，以形成独立或砌筑的植物墙和支撑物。单个角构件可用于在干燥状态下建造各种静力承重墙和支架，空腔可加固并用砂浆填充。水平接缝的榫头有多种选择，如边缘压型和插入式榫头。 此外，这些建筑构件还可按适当比例用各种材料制成混凝土建筑系统、木制家具和房间隔断或塑料模型结构（图 16）。
• Nortriptyline, haloperidol or prochlorperazine edisylate for use in the treatment of tuberculosis as well as two screening methods
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP2767275A1

  公开（公告）日：2014-08-20

  The present invention relates to a compound capable of killing mycobacteria by activating host cellular mechanisms for use in treating tuberculosis, wherein the compound is selected from the group consisting of nortriptyline, haloperidol and prochlorperazine edisylate (PE). Furthermore, the present invention relates to a pharmaceutical composition comprising the compound of the invention, and optionally a pharmaceutically acceptable carrier. The invention further relates to a method of treating tuberculosis as well as a method of identifying a lead compound for the treatment of tuberculosis.

  本发明涉及一种能够通过激活宿主细胞机制杀死分枝杆菌的化合物，用于治疗结核病，其中该化合物选自由去甲替林、氟哌啶醇和丙氯哒嗪水杨酸盐（PE）组成的组。此外，本发明还涉及一种药物组合物，该组合物包含本发明的化合物和可选的药学上可接受的载体。本发明还涉及一种治疗结核病的方法以及一种确定治疗结核病先导化合物的方法。
• MEDICAMENT FOR PREVENTION OR TREATMENT OF A METABOLIC DISORDER
  申请人：Medizinische Universität Graz

  公开号：EP3760203A1

  公开（公告）日：2021-01-06

  The present invention provides a pharmaceutical composition for use in prevention or treatment of a metabolic disorder selected from alpha-1 antitrypsin deficiency (A1AD) and lysosomal storage disease. The composition comprises a pregnane X receptor (PXR) ligand selected from the group consisting of rifampicin, hyper-forin and ursodeoxycholic acid (UDCA). Furthermore, pharmaceutical compositions, sets and an inhalation device suitable for treating said metabolic disorder are provided.

  本发明提供了一种药物组合物，用于预防或治疗选自α-1抗胰蛋白酶缺乏症（A1AD）和溶酶体贮积病的代谢紊乱。该组合物包含选自利福平、高福林和熊去氧胆酸（UDCA）组成的组的孕烷 X 受体（PXR）配体。此外，还提供了适用于治疗所述代谢紊乱的药物组合物、套装和吸入装置。
• MEDICAMENT FOR PREVENTION OR TREATMENT OF HUNTINGTON'S DISEASE
  申请人：Medizinische Universität Graz

  公开号：EP3760204A1

  公开（公告）日：2021-01-06

  The present invention provides a pharmaceutical composition for use in prevention or treatment of Huntington's disease in a human. The composition comprises a pregnane X receptor (PXR) ligand selected from rifampicin and hyperforin. Furthermore, pharmaceutical compositions and sets suitable for treating Huntington's disease are provided.

  本发明提供了一种用于预防或治疗人类亨廷顿氏病的药物组合物。该组合物包含选自利福平和金丝桃素的孕烷 X 受体（PXR）配体。此外，还提供了适用于治疗亨廷顿氏病的药物组合物和套装。
• COMPOUNDS BINDING TENASCIN-C (TNC) FOR USE IN THE TREATMENT OF DISEASES
  申请人：Université de Strasbourg

  公开号：EP3912994A1

  公开（公告）日：2021-11-24

  The invention relates compound binding Matrix Binding Motif (M-motif) on Tenascin-C (TNC) for use in the prevention and/or treatment of disease, a pharmaceutical compositions comprising compound binding Matrix Binding Motif (M-motif) on Tenascin-C (TNC) for use in the prevention and/or treatment of disease. The present invention finds applications in the therapeutic medical technical fields and also in veterinary technical fields.

  本发明涉及用于预防和/或治疗疾病的与特那斯金-C（TNC）上的基质结合基元（M-motif）结合的化合物，一种包含用于预防和/或治疗疾病的与特那斯金-C（TNC）上的基质结合基元（M-motif）结合的化合物的药物组合物。 本发明可应用于治疗医学技术领域和兽医技术领域。